Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Oxford BioMedica ( (GB:OXB) ) has provided an announcement.
Oxford BioMedica has applied for a block listing of 500,000 ordinary shares on the London Stock Exchange, with 300,000 shares allocated for its Long Term Incentive Plan and 200,000 for its Deferred Bonus Plan. The admission is expected to take effect on 28 January 2025, allowing the new shares to rank equally with existing shares. This move is part of OXB’s strategy to enhance its financial flexibility and support its growth trajectory in the cell and gene therapy sector.
More about Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapy. With over 25 years of experience, OXB provides expertise in viral vector development and manufacturing, partnering with innovative pharmaceutical and biotechnology companies to advance life-changing therapies. The company is renowned for its cutting-edge technologies and capabilities, spanning from early-stage development to commercialization, supported by strong quality-assurance systems and regulatory expertise. Headquartered in Oxford, UK, OXB operates facilities in the UK, France, and the US.
YTD Price Performance: -1.80%
Average Trading Volume: 1,863
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $542.2M
See more insights into OXB stock on TipRanks’ Stock Analysis page.
